Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

823.82
+24.743.10%
Post-market: 823.940.1200+0.01%19:58 EDT
Volume:682.68K
Turnover:558.93M
Market Cap:84.82B
PE:20.37
High:824.63
Open:808.86
Low:804.32
Close:799.08
52wk High:847.00
52wk Low:541.00
Shares:102.95M
Float Shares:98.88M
Volume Ratio:1.05
T/O Rate:0.69%
Dividend:3.64
Dividend Rate:0.44%
EPS(TTM):40.43
EPS(LYR):41.48
ROE:14.04%
ROA:6.53%
PB:2.67
PE(LYR):19.86

Loading ...

Regeneron price target lowered to $854 from $855 at Piper Sandler

TIPRANKS
·
Jul 09

Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $854 From $855

MT Newswires Live
·
Jul 09

Regeneron Pharma is Maintained at Equal-weight by Morgan Stanley

Dow Jones
·
Jul 09

Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says

MT Newswires Live
·
Jul 08

Regeneron price target lowered to $730 from $788 at Morgan Stanley

TIPRANKS
·
Jul 08

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 08

Regeneron Director Arthur F. Ryan Sells 200 Shares Worth $130,030

Reuters
·
Jul 08

Regeneron Pharma is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Jul 07

Movement Alert|Regeneron Pharmaceuticals Rises 3.06% in Regular Trading, Selected for FDA Accelerated New Production Facility Review Program

Market Focus
·
Jul 07

Regeneron price target lowered to $769 from $778 at Truist

TIPRANKS
·
Jul 07

RBC Capital Adjusts Regeneron Pharmaceuticals Price Target to $696 From $707, Maintains Sector Perform Rating

MT Newswires Live
·
Jul 07

Regeneron Pharmaceuticals Inc : Truist Securities Cuts Target Price to $769 from $778

THOMSON REUTERS
·
Jul 07

Regeneron Pharma is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Jul 06

HSBC Adjusts Price Target on Regeneron Pharmaceuticals to $800 From $990

MT Newswires Live
·
Jul 06

Regeneron price target lowered to $750 from $785 at Cantor Fitzgerald

TIPRANKS
·
Jul 06

Regeneron Pharmaceuticals - Expects Q2 2026 Bought Ipr&d Charge of $127 Mln Pre-tax - SEC Filing

THOMSON REUTERS
·
Jul 06

Regeneron Pharmaceuticals - Expects Q2 2026 Gaap and Non-gaap Net Income Per Diluted Share to Decrease by $1 - SEC Filing

THOMSON REUTERS
·
Jul 06

Regeneron Pharmaceuticals Inc Q2 Shr View $10.81

THOMSON REUTERS
·
Jul 06

U.S. Research Roundup-east West Bancorp, First Citizens Bancshares, UMB Financial

Reuters
·
Jul 06

Eli Lilly, Regeneron Among First Companies Selected for FDA Initiative to Speed Review of New Manufacturing Facilities - CNBC

Reuters
·
Jul 06